SCHEMBL6355877

SCHEMBL6355877

Clc1cccc(Cn2nnnc2-c2cccc(Cl)c2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 7/20 0.76
KMT2A Q03164 2/20 0.66
CYP1A2 P05177 2/20 0.66
MEN1 O00255 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
POLB P06746 2/20 0.61
HTT P42858 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HSD11B1 P28845 1/20 0.55
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HDAC6 Q9UBN7 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357652 0.93 P2RX7 (0.67) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL6354797 0.90 HTT (0.73) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL6357908 0.87 POLB (0.84) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL6358994 0.87 POLB (0.84) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL4403732 0.79 P2RX7 (0.81) P2RX7KMT2APOLBHTTL3MBTL1
SCHEMBL5813964 0.78 P2RX7 (0.61) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL5815172 0.78 P2RX7 (0.61) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL6355088 0.78 HTT (0.82) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL6357688 0.78 P2RX7 (0.55) P2RX7KMT2ACYP1A2MEN1CYP2C9
SCHEMBL5820209 0.77 P2RX7 (0.72) P2RX7KMT2APOLBHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 P2RX7 448/4885KMT2A 1711/4885CYP1A2 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.